NAVB
Navidea Biopharmaceuticals Inc.
NAVB
NAVB
Delisted
NAVB was delisted on the 5th of October, 2023.
28 hedge funds and large institutions have $410K invested in Navidea Biopharmaceuticals Inc. in 2022 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 7 reducing their positions, and 3 closing their positions.
New
Increased
Maintained
Reduced
Closed
more first-time investments, than exits
New positions opened: | Existing positions closed:
more funds holding
Funds holding: →
more capital invested
Capital invested by funds: $ → $
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
25% less call options, than puts
Call options by funds: $3K | Put options by funds: $4K
Holders
28
Holding in Top 10
–
Calls
$3K
Puts
$4K
Top Buyers
| 1 | +$33.9K | |
| 2 | +$19.7K | |
| 3 | +$13.3K | |
| 4 |
Renaissance Technologies
New York
|
+$8.46K |
| 5 |
TSS
Two Sigma Securities
New York
|
+$4.44K |
Top Sellers
| 1 | -$48K | |
| 2 | -$10K | |
| 3 | -$9.53K | |
| 4 |
Hudson Bay Capital Management
Stamford,
Connecticut
|
-$3K |
| 5 |
VF
Virtu Financial
New York
|
-$948 |